V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330005017 | 330002414 | 1.56 | 70.8 | Neo-adjuvant (N) | 2016-06-10 | 2016-06-25 | Cisplatin+Doxorubicin+Etoposide 28d | N | N | 330021138 | CISPLATIN + DOX + ETOPOSIDE |
| 330005018 | 330002415 | 1.72 | 65.8 | Palliative (P) | 2013-11-29 | 2013-11-29 | ALL UKALL2011 IndB Std Dex (PegAsp) | 2 | N | 330021144 | CISPLATIN + FLUOROURACIL + RT |
| 330005019 | 330002415 | null | 113.2 | Curative (C) | null | 2014-01-25 | VAC | null | N | 330021144 | FLUOROURACIL |
| 330005021 | 330007326 | 1.63 | 61.7 | Curative (C) | null | 2016-12-09 | NIVOLUMAB | null | null | 330021149 | IPILIMUMAB + NIVOLUMAB |
| 330005022 | 330007326 | 1.57 | 68 | Curative (C) | 2013-06-06 | 2013-06-11 | Docetaxel+Gemcitabine (no prior RT) | N | N | 330021149 | CYTARABINE |
| 330005023 | 330002417 | null | 68 | null | null | 2013-11-05 | VAC | N | N | 330021151 | CARBOPLATIN + VINCRISTINE |
| 330005024 | 330002418 | 0 | 5.2 | Disease modification (D) | null | 2016-12-29 | Paclitaxel (2 or 3 weekly) | N | N | 330021153 | CARBOPLATIN + DOCETAXEL |
| 330005025 | 330002418 | 1.83 | null | Curative (C) | 2017-11-14 | 2017-11-14 | Chlorambucil | N | N | 330021153 | CARBOPLATIN + CETUXIMAB + FLUOROURACIL |
| 330005029 | 330002420 | 1.82 | 54.9 | Palliative (P) | 2013-11-06 | 2013-11-18 | Mitotane 3 - 3.5g | N | N | 330021193 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + IFOSFAMIDE + VINCRISTINE |
| 330005030 | 330002420 | 1.61 | 38 | Palliative (P) | 2015-06-05 | 2015-10-09 | Azacitidine | 02 | N | 330021193 | METHOTREXATE HIGH DOSE |
| 330005031 | 330002420 | 1.64 | 0 | Palliative (P) | 2017-10-01 | 2017-10-01 | PEMBROLIZUMAB | 02 | N | 330021193 | CHLORAMBUCIL |
| 330005032 | 330002420 | null | 64.3 | Disease modification (D) | 2016-12-18 | 2016-12-29 | R Chlorambucil | N | N | 330021193 | BEP |
| 330005033 | 330002420 | 1.74 | 69.15 | null | 2013-06-28 | 2013-06-29 | BEP 5 Day | N | N | 330021193 | CHOP R |
| 330005034 | 330002420 | 1.67 | 70 | Disease modification (D) | 2016-07-09 | 2016-07-14 | Hydroxycarbamide | N | N | 330021193 | AML16 TRIAL |
| 330005035 | 330002420 | 1.6 | 116.2 | null | null | 2016-05-14 | Carboplatin + Doxorubicin | N | N | 330021193 | UKALL2011 |
| 330005036 | 330002420 | 1.7 | 63.05 | Curative (C) | 2013-08-27 | 2013-08-31 | GC Int Guide Excranial GermCell JEB | null | null | 330021193 | TEMOZOLOMIDE |
| 330005037 | 330002420 | null | 145.2 | Palliative (P) | 2016-03-30 | 2016-03-30 | Capecitabine 35days + RT | null | null | 330021193 | VEIP |
| 330005038 | 330002420 | 1.6 | 62.1 | Curative (C) | 2015-05-05 | 2015-05-05 | CHOP R | 02 | N | 330021193 | IMATINIB |
| 330005039 | 330002420 | 1.69 | 64.1 | Palliative (P) | 2014-04-06 | 2014-04-09 | Methotrexate + Folinic acid | 02 | N | 330021193 | HYDROXYCARBAMIDE |
| 330005040 | 330002420 | 0 | 102.7 | Palliative (P) | 2016-09-01 | 2016-09-01 | CYCLOPHOSPHAMIDE + FLUDARABINE | 2 | N | 330021193 | OXALIPLATIN + MDG |
| 330005041 | 330002420 | 1.76 | 67 | null | null | 2016-09-03 | STREPTOZOCIN | null | null | 330021193 | CARBOPLATIN + RT |
| 330005042 | 330002421 | 1.64 | 50.6 | Palliative (P) | 2012-12-12 | 2013-06-11 | CYCLO + DOXORUBICIN + VINCRISTINE | 02 | N | 330021254 | VIDE |
| 330005043 | 330002421 | 1.69 | 138 | Adjuvant (A) | 2014-09-20 | 2014-09-28 | TCF | N | N | 330021254 | CARBOPLATIN + RT |
| 330005044 | 330002421 | null | 89.9 | Adjuvant (A) | 2015-09-10 | 2015-09-12 | CYCLOPHOSPHAMIDE | Y | N | 330021254 | MITOTANE |
| 330005045 | 330002422 | null | 82.2 | Palliative (P) | 2013-07-24 | 2013-07-24 | FLAG + Idarubicin | null | N | 330021271 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 330005046 | 330002423 | null | 95 | Palliative (P) | 2016-10-14 | 2016-11-01 | FLUOROURACIL + MITOMYCIN + RT | N | N | 330021283 | METHOTREXATE INTRATHECAL |
| 330005047 | 330002424 | null | 0 | Curative (C) | null | 2016-07-31 | Cytarabine High Dose | null | null | 330021284 | VIDE |
| 330005048 | 330002425 | 1.76 | 67.5 | Palliative (P) | 2017-08-30 | 2017-09-07 | ETOPOSIDE + IFOSFAMIDE | Y | N | 330021287 | PEMBROLIZUMAB |
| 330005049 | 330002425 | 1.74 | null | Adjuvant (A) | 2016-11-28 | 2016-11-28 | CAPECITABINE + CETUXIMAB + CISPLATIN | 2 | N | 330021287 | UKALL60+ |
| 330005050 | 330002425 | null | 97 | Adjuvant (A) | 2017-01-15 | 2017-01-20 | AML18 PILOT TRIAL | N | N | 330021287 | DOCETAXEL + GEMCITABINE |
| 330005051 | 330002425 | null | null | Disease modification (D) | 2014-06-26 | 2014-06-26 | Paclitaxel 7 day | Y | N | 330021287 | AML18 TRIAL |
| 330005052 | 330012254 | 1.72 | 98 | Palliative (P) | 2013-01-28 | 2013-01-28 | VAC | N | N | 330021300 | BEP |
| 330005053 | 330002426 | 1.51 | 81 | Curative (C) | 2015-02-02 | 2015-02-09 | EDP + MITOTANE | 02 | N | 330021301 | ADE |
| 330005054 | 330002426 | 1.66 | 15.4 | Curative (C) | 2016-05-22 | 2016-05-22 | PEMBROLIZUMAB | N | N | 330021301 | PCV |
| 330005060 | 330012701 | 1.61 | 97.7 | Palliative (P) | 2017-03-31 | 2017-04-28 | Chlorambucil | N | Y | 330021317 | NIVOLUMAB |
| 330005061 | 330012701 | 0 | 54.5 | Disease modification (D) | 2013-10-21 | 2013-11-21 | CISPLATIN + DOX + ETOPOSIDE + MITOTANE | 1 | N | 330021317 | PEMBROLIZUMAB |
| 330005062 | 330012701 | 1.7 | 99.9 | Palliative (P) | 2013-03-02 | 2013-03-09 | Paclitaxel 80mg/m2 day 1 8 15 | Y | N | 330021317 | CHLORAMBUCIL + RITUXIMAB |
| 330005063 | 330012701 | 1.82 | 101 | Curative (C) | 2013-07-04 | 2013-07-04 | POMB | 02 | null | 330021317 | AML19 TRIAL |
| 330005064 | 330012701 | 1.5 | 56 | Palliative (P) | 2018-09-30 | 2018-09-30 | VAI (Ifos 3g/m2) | 99 | null | 330021317 | FLAG + IDARUBICIN |
| 330005066 | 330002429 | 1.76 | 98 | Palliative (P) | 2013-07-28 | 2013-07-28 | CHOP | N | N | 330021330 | LIPOSOMAL DAUNORUBICIN |
| 330005067 | 330002430 | 1.77 | 79.9 | null | 2014-01-10 | 2014-01-14 | BORTEZOMIB + RITUXIMAB | N | N | 330021334 | LI-1 TRIAL |
| 330005068 | 330002431 | 1.78 | null | Curative (C) | 2013-11-11 | 2013-11-11 | ECX | null | null | 330021340 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 330005069 | 330002432 | null | 104.6 | null | null | 2016-02-05 | Chlorambucil | null | null | 330021342 | CARBOPLATIN + VINCRISTINE |
| 330005070 | 330002432 | 1.58 | 54.9 | Disease modification (D) | 2017-01-30 | 2017-02-15 | Epirubicin (weekly) | null | N | 330021342 | DOXORUBICIN + OLARATUMAB |
| 330005073 | 330002434 | null | 47.8 | Palliative (P) | 2016-07-29 | 2016-07-30 | Doxorubicin + Olaratumab | 2 | N | 330021361 | IPILIMUMAB |
| 330005074 | 330002434 | null | null | Curative (C) | 2015-05-21 | 2015-05-25 | VAI (Ifos 3g/m2) | null | N | 330021361 | HYDROXYCARBAMIDE |
| 330005075 | 330002435 | 1.65 | 86.3 | Neo-adjuvant (N) | 2015-04-08 | 2015-04-08 | Ipilimumab | N | null | 330021363 | ATG + BUSULFAN + FLUDARABINE |
| 330005076 | 330002435 | 0 | 77 | Not known (9) | 2017-09-14 | 2017-10-02 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 330021363 | METHOTREXATE |
| 330005077 | 330002436 | 1.53 | 76 | Palliative (P) | 2014-10-08 | 2014-10-29 | PEMBROLIZUMAB | N | N | 330021366 | FLUOROURACIL + MITOMYCIN |
| 330005078 | 330002436 | 0 | 72.3 | Curative (C) | 2018-03-04 | 2018-03-17 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | 02 | N | 330021366 | IMATINIB |